UNSPSC 51283707: Ceforanide

This classification denotes a cephalosporin antibiotic with the molecular formula C20H21N7O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M1YF8951V, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-trans)- but generally known as ceforanide, which bears US NIH Compound Identifier 43507.

UNSPSC 51283707 Ceforanide, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code nominally describes a specific pharmaceutical active pharmaceutical ingredient, but the recent opportunities tagged under it involve procurement of finished pharmaceutical products and medical supplies—Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through a wholesale piggyback contract, and Naloxone with drug deactivation systems through a county competitive bid. State and local health departments and counties are the issuing bodies, but the work being solicited does not match the code's pharmaceutical-ingredient name. The recent record shows no solicitation for Ceforanide itself, only finished-form pharmaceuticals and medical devices.

The Illinois Department of Public Health awarded a $2.999 million pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Bid 26-482DPH-PREPD-B-53392) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets over a 12-month initial term with two renewal options. Seminole County, Florida solicited 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually via IFB 60459723LAS, due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building. Neither opportunity specifically procures Ceforanide. The code shows little relevant recent activity under its stated scope; prospecting under this code appears unlikely to yield opportunities for Ceforanide supply.